GLSI Greenwich LifeSciences Inc

Price (delayed)

$23.95

Market cap

$351.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.43

Enterprise value

$345.37M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 2

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a ...

Highlights
The net income has contracted by 11% YoY but it has grown by 8% from the previous quarter
GLSI's EPS is up by 10% since the previous quarter but it is down by 7% year-on-year
The equity has shrunk by 84% QoQ and by 61% YoY
The quick ratio has plunged by 55% from the previous quarter and by 17% YoY

Key stats

What are the main financial stats of GLSI

GLSI stock price

How has the Greenwich LifeSciences stock price performed over time
Intraday
-1.4%
1 week
-17.39%
1 month
8.96%
1 year
156.42%
YTD
13.99%
QTD
-0.29%

Financial performance

How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.45M
Net income
-$19.36M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 11% YoY but it has grown by 8% from the previous quarter
The operating income has declined by 10% year-on-year but it is up by 8% since the previous quarter

Price vs fundamentals

How does GLSI's price correlate with its fundamentals

Growth

What is Greenwich LifeSciences's growth rate over time

Valuation

What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
939.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS is up by 10% since the previous quarter but it is down by 7% year-on-year
The equity has shrunk by 84% QoQ and by 61% YoY

Efficiency

How efficient is Greenwich LifeSciences business performance
The ROA has shrunk by 59% YoY but it has increased by 20% QoQ

Dividends

What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLSI.

Financial health

How did Greenwich LifeSciences financials performed over time
GLSI's total assets is 6% greater than its total liabilities
The company's total liabilities has surged by 83% YoY
GLSI's total assets has surged by 62% since the previous quarter and by 51% year-on-year
The company's debt is 100% lower than its equity
The equity has shrunk by 84% QoQ and by 61% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.